Novo Nordisk’s shares declined 8% after the company’s Capital Markets Day failed to reassure investors about its ability to sustain growth beyond the expiration of semaglutide exclusivity in key markets by the early 2030s. The Danish pharmaceutical giant, best known for its diabetes and weight-loss drugs Ozempic and Wegovy, announced a pipeline of over five potential blockbuster drugs by 2030 but fell short of convincing markets that it has a credible strategy to outpace rivals like Eli Lilly, whose shares have risen 58% over the past year. Analysts at Barclays and Jefferies noted limited confidence-inducing disclosures, with Jefferies stating the presentation did not ‘derisk the trajectory or offer a strategic reset.’
CEO Maziar Mike Doustdar acknowledged the market’s reaction as a sign that investor trust remains fragile. ‘The reaction of the market is a testament that we still need to do more work on building trust of the market,’ he said. Doustdar emphasized that credibility would be rebuilt through consistent financial and scientific results, delivered quarter by quarter, while stressing that the company would not deviate from its strategic direction. ‘Our job is to not deviate from our strategic direction and continue outperforming our own expectations,’ he stated.
Doustdar’s approach contrasts with his earlier focus on simplifying Novo’s portfolio to concentrate on diabetes and obesity when he took the helm in August 2025. However, he argued that the company’s early-stage pipeline had expanded significantly outside these core areas—up fourfold in the past three to four years—while its core pipeline remained flat. Now, he said, it is time to broaden ambitions into cardiovascular, liver, and blood disorders, though he acknowledged skepticism over whether Novo’s portfolio remains sufficiently diversified. Jefferies noted that obesity remains a dominant focus despite the push for diversification.
The company’s strategy hinges on a fragmented obesity market, where patients and physicians may prioritize factors beyond weight loss, such as side effects, muscle preservation, and convenience. Novo is developing drugs targeting moderate weight loss with fewer side effects, as well as treatments for obesity-related conditions. Its pipeline includes CagriSema, slated for 2027, and next-generation oral drugs like zenagamtide. A survey of 37,000 obese patients found varied priorities, with some seeking maximum weight loss and others prioritizing quality of life and treatment convenience.
Doustdar’s scientific lead, Martin Holst Lange, emphasized that Novo’s oral franchise remains a competitive advantage, with over 80% of U.S. Wegovy users previously untouched by GLP-1 treatments. The company aims to scale production to treat 10 times more obese patients by 2030, including four additional oral obesity assets. However, analysts like Citi remain cautious, forecasting mid-single-digit annual growth for the obesity market until 2030 and reiterating a neutral rating on the stock. The upcoming launches of Wegovy outside the U.S. will be a critical test of Novo’s strategy.
While Doustdar dismissed the perception of a ‘U-turn,’ investors remain concerned about the patent cliff looming for semaglutide and the need for tangible results to restore confidence. The company’s ability to diversify its pipeline while maintaining profitability will be central to its long-term viability.
